Cytek Biosciences (CTKB) said Monday it approved a stock repurchase program for up to $50 million of its common stock to succeed the Dec. 31 expiration of its existing $50 million repurchase program.
The new buyback authorization commences Jan. 1 and remains in effect until the end of 2025, the company said.
The biotech company said the program may be changed or ended at its discretion.
Shares of the company were up more than 1% in Monday's premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.